On Saturday 16th June an oral abstract session took place at the 23rd congress of the European Hematology Association (EHA). Abstract S803 was presented by Anas Younes, Memorial Sloan Kettering Cancer Center, New York, US, on the efficacy and safety of atezolizumab plus R-CHOP.
The results of the interim analysis were presented of a phase I/II study on the use of atezolizumab, an anti-PD-L1 antibody, in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) (NCT02596971). The primary endpoint was complete response (CR) by PET-CT and safety. The secondary endpoints were objective response rate (ORR), duration of response (DOR) and progression-free survival (PFS) by investigator assessment and MRD.
- 42 patients were inducted and included in the interim safety analysis and 15 patients completed the induction and were included in the interim efficacy analysis
- The ORR at the end of induction (n = 15), was 87% as per the modified Lugano 2014 and Cheson 2007 by both the independent review committee and investigator assessment
- MRD was evaluated at 10-5 sensitivity using Adaptive ImmunoSEQ® NGS platform (v2). 15 patient samples were collected at baseline and it was found that 5 patients were MRD negative at the end of induction
- At induction, adverse events (AEs) Grade 3-4 occurred in 64% and at consolidation Grade 3-4 AEs occurred in 15%
Dr Younes concluded that at the interim analysis, R-CHOP with atezolizumab showed encouraging activity in patients with previously untreated DLBCL with a manageable safety profile.
Younes A. Atezolizumab plus R-CHOP shows encouraging activity and acceptable toxicity in previously untreated patients with diffuse large B-cell lymphoma (DLBCL): An interim analysis of a phase I/II study. Abstract S803. 23rd Congress of EHA, Stockholm, Sweden